Kynurenine pathway - A new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients

Advances in Medical Sciences

Volumn 55, Issue 2, 2010, Pages 196-203

  Pawlak, K ^a   Mysliwiec M ^a   Pawlak, D ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

atherosclerosis; chronic kidney disease; endothelial dysfunction; kynurenines

Indexed keywords

3 HYDROXYKYNURENINE; ANTHRANILIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; KYNURENIC ACID; KYNURENINE; PADGEM PROTEIN; QUINOLINIC ACID; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 78650464386     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-010-0015-6     Document Type: Article

References (39)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9.
2. Papagianni A, Kokolina E, Kalovoulos M, Vainas A, Dimitriadis C, Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2004 May;19(5):1258-63.
3. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant. 2003 Jan;18(1):113-9.
4. Pawlak K, Naumnik B, Brzósko S, Pawlak D, Mysliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol. 2004 Jan-Feb;24(1):154-61.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26.
6. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003 Oct;170(2):191-203.
7. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathology of vascular disorders. Blood. 1998 May 15;91(10):3527-61.
8. Jacobson SH, Egberg N, Hylander B, Lundahl J.Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol. 2002 Jan-Feb;22(1):42-7.
9. Malyszko J, Malyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res. 2004;27(2):71-7.
10. Schroecksnadel K, Frick B, Winkler C, Fusch D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006 Jul;4(3):205-13.
11. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. 1993 Sep;45(3):309-79.
12. Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolism in the rat with experimental renal insufficiency. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):755-66.
13. Pawlak D, Tankiewicz A, Matys T, Buczko W. Peripheral distribution of kynurenine metabolism and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol. 2003 Jun;54(2):175-89.
14. Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001;33(2):399-404.
15. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis. 2009 May;204(1):309-14.
16. Pawlak K, Brzosko S, Mysliwiec M, Pawlak D. Kynurenine, quinolinic acid-the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis. 2009 Jun;204(2):561-6.
17. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003 May;18(5):892-8.
18. Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, Pecoits-Filho R. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111(2):c117-26.
19. Stenvinkel P, Lindholm B, Heimbürger M, Heimbürger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: Association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant. 2000 Oct;15(10):1624-30.
20. Suliman ME, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: A predictor of outcome. Nephrol Dial Transplant. 2006 Jun;21(6):1603-10.
21. Hansen AM, Ball HJ, Mitchell AJ, Miu J, Takikawa O, Hunt NH. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. Int J Parasitol. 2004 Nov;34(12):1309-19.
22. Stazka J, Luchowski P, Wielosz M, Kleinrok Z, Urbanska EM. Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings expose to L-kynurenine. Eur J Pharmacol. 2002 Jul 19;448(2-3):133-7.
23. Wejksza K, Rzeski W, Parada-Turska J, Zdzisinska B, Rejdak R, Kocki T, Okuno E, Kandefer-Szerszen M, Zrenner E, Turski WA. Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):300-4.
24. Stazka J, Luchowski P, Urbanska EM. Homocysteine, a risk factor for atherosclerosis, biophasically changes the endothelial production of kynurenic acid. Eur J Pharmacol. 2005 Jul 11;517(3):217-23.
25. Urbanska EM, Luchowski P, Luchowska E, Pniewski J, Wozniak R, Chodakowska-Zebrowska M, Lazarewicz J. Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: A study in stroke patients. Pharmacol Rep. 2006 Jul-Aug;58(4):507-11.
26. Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009 Jul 17;284(29):19189-95.
27. Wejksza K, Rzeski W, Turski WA. Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells. Pharmacol Rep. 2009 Jul-Aug;61(4):751-6.
28. Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009 Jun;24(6):1901-8.
29. Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998 Jan;70(1):299-307.
30. Santamaria A, Flores-Escartin A, Martinez JC, Osorio L, Galvan-Arzate S, Chaverri JP, Maldonado PD, Medina-Campos ON, Jimenez-Capdeville ME, Manjarrez J, Rios C. Copper blocks quinolinic acid neurotoxicity in rats: Contribution of antioxidant systems. Free Radic Biol Med. 2003 Aug 15;35(4):418-27.
31. Schnabel R, Blankenberg S. Oxidative stress in cardiovascular disease. Successful translation from bench to bedside? Circulation. 2007 Sep 18;116(12):1338-40.
32. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan- Vague I; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004 Mar 23;109(11):1343-8.
33. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 Mar 9;332(10):635-41.
34. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999 Aug 17;100(7):736-42.
35. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, Wunsch A, Allenberg J, Kubler W, Bode C. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin and thrombomodulin. Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):505-12.
36. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- moce. Am J Pathol. 2000 Dec;157(6):1819-24.
37. Rudzite V, Sileniece G, Liepina D, Dalmane A, Zirne R. Impairment of kynurenine metabolism in cardiovascular disease. Adv Exp Med Biol. 1991;294:663-7.
38. Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, Trusinskis K, Fuchs D. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 2003 Jul;33(7):550-4. (Pubitemid 36783213)
39. Pertovaara M, Raitala A, Juonala M, Lehtimäki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: The Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007 Apr;148(1):106-11.